ArticleFrontiers in endocrinology2020
Adiponectin Paradox in Alzheimer's Disease; Relevance to Amyloidogenic Evolvability?
Article in Frontiers in endocrinology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 29 citations in OpenAlex.
- Hippocampal AdipoR1 regulates the microglial response and delays disease progression in a mouse model of Alzheimer's disease.Molecular psychiatry · 2026Article
- Vitamin D and L-Cysteine as Potential Regulators of Adiponectin in Alzheimer's Disease: A Narrative Review.Nutrients · 2026Review
- Adiponectin deficiency drives cerebrovascular dysfunction and synergizes with amyloid-β to exacerbate alzheimer's pathology.Alzheimer's research & therapy · 2026Article
- Clinical efficacy of donepezil combined with nerve growth factor in the treatment of patients with Parkinson's disease dementia and its impact on adiponectin and soluble tumor necrosis factor-alpha receptor-1.Pakistan journal of medical sciences · 2025Article
- Reversal of neuronal tau pathology via adiponectin receptor activation.Communications biology · 2025Article
- Reevaluating Adiponectin's impact on obesity hypertension: a Chinese case-control study.BMC cardiovascular disorders · 2024Article
- Adiponectin Gene Polymorphisms: A Case-Control Study on Their Role in Late-Onset Alzheimer's Disease Risk.Life (Basel, Switzerland) · 2024Article
- Cognitive impairment in patients with heart failure: molecular mechanism and therapy.Heart failure reviews · 2023Review
- Serum Adiponectin and In Vivo Brain Amyloid Deposition in Cognitively Normal Older Adults: A Cohort Study.Aging and disease · 2023Article
- Mitochondria targeting drugs for neurodegenerative diseases-Design, mechanism and application.Acta pharmaceutica Sinica. B · 2022Review
- Article
- Reconsideration of Alzheimer's Disease Therapy from a Viewpoint of Amyloidogenic Evolvability.Journal of Alzheimer's disease reports · 2022Article
- An Explanation for the Adiponectin Paradox.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Adiponectin: a pleiotropic hormone with multifaceted roles.Problemy endokrinologii · 2021Review
- Adiponectin: a potential target for obesity-associated Alzheimer's disease.Metabolic brain disease · 2021Review
- Diabetes, inflammation, and the adiponectin paradox: Therapeutic targets in SARS-CoV-2.Drug discovery today · 2021Review
- Adiponectin-mimetic novel nonapeptide rescues aberrant neuronal metabolic-associated memory deficits in Alzheimer's disease.Molecular neurodegeneration · 2021Article
- Adiponectin paradox as a therapeutic target of the cancer evolvability in aging.Neoplasia (New York, N.Y.) · 2021Review
- Therapeutic Potential ofParkinson's disease · 2021Review
- What Are the Clinical and Systemic Results of Periodontitis Treatment in Obese Individuals?Current oral health reports · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adiponectin (APN) is a multi-functional adipokine which sensitizes the insulin signals, stimulates mitochondria biogenesis, and suppresses inflammation. By virtue of these beneficial properties, APN may protect against metabolic syndrome, including obesity and type II diabetes mellitus. Since these diseases are associated with hypoadiponectinemia, it is suggested that loss of function of APN might be involved. In contrast, despite beneficial properties for cardiovascular cells, APN is detrimental in circulatory diseases, including chronic heart failure (CHF) and chronic kidney disease (CKD). Notably, such an APN paradox might also be applicable to neurodegeneration. Although APN is neuroprotective in various experimental systems, APN was shown to be associated with the severity of amyloid accumulation and cognitive decline in a recent prospective cohort study in elderly. Furthermore, Alzheimer's disease (AD) was associated with hyperadiponectinemia in many studies. Moreover, APN was sequestered by phospho-tau into the neurofibrillary tangle in the postmortem AD brains. These results collectively indicate that APN might increase the risk of AD. In this context, the objective of the present study is to elucidate the mechanism of the APN paradox in AD. Hypothetically, APN might be involved in the stimulation of the amyloidogenic evolvability in reproductive stage, which may later manifest as AD by the antagonistic pleiotropy mechanism during aging. Given the accumulating evidence that AD and CHF are mechanistically overlapped, it is further proposed that the APN paradox of AD might be converged with those of other diseases, such as CHF and CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.